AskMed

Atorvastatin Statin: How It Compares With Other Statins

Atorvastatin is a statin, one of the HMG-CoA reductase inhibitors that lower LDL cholesterol, and it has been tested in outcome trials from primary prevention to acute coronary syndrome and stroke. What sets the atorvastatin statin profile apart from the others is a mix of traits: it is lipophilic, it is cleared mainly through the CYP3A4 enzyme, its active metabolites keep it working for 20 to 30 hours, and less than 2% of it leaves through the urine. With rosuvastatin, it is one of only two statins that reach high intensity in the 2018 ACC/AHA cholesterol guideline. This guide sets atorvastatin next to rosuvastatin, simvastatin, pravastatin, pitavastatin, lovastatin and fluvastatin, explains the intensity groups in words, summarizes the trials behind it and lists what guides the choice of statin. It gives no doses; those belong to the label and the prescriber.

Comparing statins means holding several sources side by side: a guideline's intensity table, five FDA labels and a shelf of trials. AskMed is a medical question app made for doctors, nurses, pharmacists, medical students and researchers. It searches journals, clinical guidelines and drug labels first, then writes an answer with a link after every claim. A resident preparing for a lipid clinic can ask how atorvastatin and rosuvastatin differ in metabolism, kidney clearance and exposure in Asian patients, and see each difference tied to the label section it comes from.

Compare two statin labels in AskMed:

What is a statin, and where does atorvastatin fit?

A statin is a drug that inhibits HMG-CoA reductase, the enzyme that sets the pace of cholesterol synthesis in the liver, and atorvastatin is one of seven statins in clinical use. The other six are rosuvastatin, simvastatin, pravastatin, pitavastatin, lovastatin and fluvastatin. When liver cells make less cholesterol, they pull more LDL out of the blood, and that is how every statin lowers LDL cholesterol. The Cholesterol Treatment Trialists' (CTT) meta-analysis of 26 randomized trials and about 170,000 participants found that each 1.0 mmol/L fall in LDL cholesterol cut the yearly rate of major vascular events by just over a fifth, and all-cause mortality by 10%. That shared mechanism is why guidelines treat statins as a class. Yet the seven molecules differ in how they dissolve, which enzymes clear them, how long they act and how far they can push LDL down, and those differences decide where atorvastatin is the natural pick and where another statin fits better.

The FDA label for atorvastatin (Lipitor) reflects that trial base. It lists reducing the risk of heart attack, stroke, revascularization and angina in adults with several coronary risk factors but no clinically evident coronary disease, reducing heart attack and stroke in adults with type 2 diabetes and risk factors, and reducing events in adults who already have coronary heart disease, alongside lowering LDL cholesterol in several lipid disorders, including familial hypercholesterolemia from age 10.

How does atorvastatin differ from other statins?

Atorvastatin differs from other statins in four measurable ways: solubility, the enzyme that clears it, how long it acts and how little the kidneys handle it. Climent and colleagues (2021) group atorvastatin with simvastatin, lovastatin, fluvastatin and pitavastatin as lipophilic statins, which enter cells by passive diffusion and spread widely through tissues, while rosuvastatin and pravastatin are hydrophilic and rely on liver transporters, which makes them more liver-selective. The Lipitor label says in vitro studies point to CYP3A4 as the main route of metabolism, the same enzyme that clears simvastatin and lovastatin. Rosuvastatin is not extensively metabolized, with about 10% recovered as a metabolite formed mainly by CYP2C9, and pitavastatin is cleared mostly by glucuronidation. Atorvastatin's plasma half-life is about 14 hours, but active metabolites provide about 70% of its circulating activity and stretch the inhibitory effect to 20 to 30 hours. Less than 2% of it is recovered in urine.

Seven statins compared Statin Solubility · clearance · half-life Atorvastatin Lipophilic · CYP3A4 · ~14 h High or moderate intensity Rosuvastatin Hydrophilic · minor CYP2C9 · ~19 h High or moderate intensity Simvastatin Lipophilic · CYP3A4 · 1–2 h Moderate or low intensity Pravastatin Hydrophilic · no major CYP · 1–2 h Moderate or low intensity Pitavastatin Lipophilic · minor CYP2C9 · ~12 h Moderate intensity only Lovastatin Lipophilic · CYP3A4 · ~2 h Moderate or low intensity Fluvastatin Lipophilic · CYP2C9 · ~4.7 h Moderate or low intensity
Solubility and half-lives from Climent and colleagues (2021) and the FDA labels; intensity groups from Table 3 of the 2018 ACC/AHA guideline. Atorvastatin's active metabolites extend its inhibitory activity to 20–30 hours.

Kidney handling is where the hydrophilic statins part ways with atorvastatin. The Lipitor label states that renal disease has no influence on its plasma concentrations or on its LDL lowering. The pravastatin label reports about 20% of an oral dose in urine, and the Crestor label reports that rosuvastatin levels rise about 3-fold in severe renal impairment in people not on hemodialysis. The Livalo label reports pitavastatin exposure about twice as high in moderate renal impairment. Half-life also explains why atorvastatin, rosuvastatin and pitavastatin act for longer, while simvastatin, pravastatin and lovastatin are cleared within a few hours.

What do high-, moderate- and low-intensity statins mean?

Statin intensity describes how much a statin regimen lowers LDL cholesterol on average, and the 2018 AHA/ACC cholesterol guideline sorts every regimen into three groups. High-intensity statin therapy typically lowers LDL cholesterol by 50% or more, moderate-intensity therapy by 30% to 49%, and low-intensity therapy by less than 30%. Only atorvastatin and rosuvastatin reach the high-intensity group, at the upper end of their ranges; used less intensively, both fall into the moderate group. Simvastatin, pravastatin, lovastatin and fluvastatin appear in the moderate and low groups, and pitavastatin appears only in the moderate group. The guideline adds two caveats: the size of LDL lowering varies in practice, and certain Asian populations may respond more strongly to certain statins. Intensity, not brand, is what the recommendations are written in, so the first question when choosing a statin is which intensity the patient needs, and the second is which molecule delivers it best for that patient.

≥50%LDL lowering: high intensity, atorvastatin or rosuvastatin only
30–49%LDL lowering: moderate intensity, reached by all seven statins
<30%LDL lowering: low intensity, simvastatin, pravastatin, lovastatin or fluvastatin

NICE uses its own three tiers (low, medium and high) in guideline NG238, and it also lists only atorvastatin and rosuvastatin as high intensity, while pravastatin appears only in the low tier. NICE sets targets rather than a fixed percentage alone: for primary prevention it aims for a reduction of more than 40% in non-HDL cholesterol, and for secondary prevention an LDL cholesterol of 2.0 mmol/L or less, or a non-HDL cholesterol of 2.6 mmol/L or less.

Which patients need which statin intensity?

The 2018 AHA/ACC guideline matches statin intensity to four groups of patients rather than to a single LDL target. Adults with clinical atherosclerotic cardiovascular disease (ASCVD), such as a past heart attack, stroke or peripheral artery disease, should take high-intensity or maximally tolerated statin therapy, aiming to lower LDL cholesterol by 50% or more. Adults with severe primary hypercholesterolemia, an LDL cholesterol of 190 mg/dL (4.9 mmol/L) or more, start high-intensity therapy without a risk calculation. Adults aged 40 to 75 with diabetes and an LDL of 70 mg/dL (1.8 mmol/L) or more start moderate-intensity therapy, and high intensity is reasonable when they have several risk factors or are 50 to 75. Other adults aged 40 to 75 are treated by estimated 10-year risk after a clinician–patient discussion: if a statin is indicated, the aim is at least a 30% LDL reduction, and at least 50% when the 10-year risk is 20% or higher.

  1. Clinical ASCVD: high-intensity or maximally tolerated statin, LDL down by 50% or more.
  2. LDL 190 mg/dL or more: high-intensity statin without calculating 10-year risk.
  3. Diabetes, age 40–75: moderate intensity; high intensity reasonable with several risk factors.
  4. Primary prevention, age 40–75: by 10-year risk; risk-enhancing factors or a calcium score can tip the decision.
The four statin benefit groups of the 2018 AHA/ACC cholesterol guideline.

Because only atorvastatin and rosuvastatin reach high intensity, the first two groups narrow the choice to those two molecules from the start. For adults older than 75, the guideline notes that trial evidence is not strong and asks for a clinician–patient risk discussion before starting or continuing a statin. Real patients rarely sit cleanly in one group: someone with diabetes, chronic kidney disease and a borderline risk score touches three. A medical student or resident can put that whole picture to AskMed, for example which intensity the 2018 guideline supports for a 62-year-old with type 2 diabetes, albuminuria and an LDL of 3.4 mmol/L, and get the recommendation with a link to the guideline section it comes from.

Check a statin-intensity decision against the 2018 guideline in AskMed:

What did the landmark atorvastatin trials show?

The landmark atorvastatin trials showed fewer heart attacks and strokes across populations that earlier statin trials had not settled: people with hypertension, people with type 2 diabetes and people after a stroke. In ASCOT-LLA (2003), 10,305 hypertensive patients aged 40 to 79 with at least three other risk factors and a total cholesterol of 6.5 mmol/L or less were given atorvastatin or placebo; the trial was stopped after a median 3.3 years, with non-fatal heart attack and fatal coronary disease reduced (hazard ratio 0.64) and fatal and non-fatal stroke also lower (hazard ratio 0.73). In CARDS (2004), 2,838 adults aged 40 to 75 with type 2 diabetes, no cardiovascular disease and at least one further risk factor had a 37% lower rate of major cardiovascular events and a 48% lower rate of stroke over a median 3.9 years, and the trial stopped 2 years early for benefit. Both used a moderate-intensity regimen.

HR 0.64coronary events in hypertension, ASCOT-LLA
−37%major cardiovascular events in type 2 diabetes, CARDS
HR 0.84recurrent stroke after stroke or TIA, SPARCL
−16%events after acute coronary syndrome, intensive vs standard, PROVE IT

Two further trials tested high-intensity atorvastatin. SPARCL (2006) enrolled 4,731 people who had a stroke or transient ischemic attack (TIA) in the previous one to six months, an LDL of 100 to 190 mg/dL and no known coronary disease. Over a median 4.9 years, fatal or non-fatal stroke occurred in 11.2% on atorvastatin and 13.1% on placebo (adjusted hazard ratio 0.84), although hemorrhagic strokes were more frequent (55 against 33). PROVE IT-TIMI 22 (2004) randomized 4,162 patients within 10 days of an acute coronary syndrome to intensive atorvastatin or standard pravastatin therapy: at two years the composite endpoint occurred in 22.4% against 26.3%, a 16% reduction in the hazard. The CTT meta-analysis later pooled more against less intensive statin regimens and found a further 15% reduction in major vascular events.

Trial details are where clinical questions get specific: who was excluded, what the comparator was, whether a subgroup result holds. AskMed searches the published papers before it answers, so a clinician reviewing secondary stroke prevention can ask what SPARCL found on hemorrhagic stroke and which patients were at higher risk, and read the answer with the paper linked beside each figure.

Look up what an atorvastatin trial enrolled and found in AskMed:

Atorvastatin or rosuvastatin: what does head-to-head evidence show?

Atorvastatin and rosuvastatin performed alike on hard outcomes in the largest head-to-head trial, LODESTAR, published in the BMJ in 2023. The trial randomized 4,400 adults with coronary artery disease at 12 hospitals in South Korea to rosuvastatin or atorvastatin and followed them for three years. The composite of death, heart attack, stroke or any coronary revascularization occurred in 8.7% of the rosuvastatin group and 8.2% of the atorvastatin group (hazard ratio 1.06, not significant). Mean LDL cholesterol during treatment was slightly lower with rosuvastatin, 1.8 against 1.9 mmol/L. The safety results leaned the other way: new-onset diabetes needing medicine was more common with rosuvastatin (7.2% against 5.3%), and so was cataract surgery (2.5% against 1.5%). LODESTAR was open label and enrolled only Korean patients, so its results may not transfer to every population, but it is the most direct outcome comparison the two high-intensity statins have.

Two label details separate the pair in practice. The Crestor label reports about a 2-fold higher exposure to rosuvastatin in Asian people compared with a White control group, which matches the 2018 guideline's note that certain Asian populations respond more strongly. And as noted above, rosuvastatin levels rise in severe kidney impairment while atorvastatin levels do not. NICE NG238 treats the two as interchangeable within the high-intensity group: if a person has adverse effects on a high-intensity statin, one of the strategies it lists is switching to a different statin in the same intensity group, which it spells out as rosuvastatin for someone already taking atorvastatin.

What guides the choice of statin?

The choice of statin follows from the intensity a patient needs, then from the patient's medicines, kidney and liver function, ancestry and past side effects. When high intensity is needed, the choice is atorvastatin or rosuvastatin. Interacting medicines come next: atorvastatin, simvastatin and lovastatin depend on CYP3A4, so strong CYP3A4 inhibitors raise their levels and the risk of muscle injury. The Zocor label contraindicates simvastatin with strong CYP3A4 inhibitors, cyclosporine, danazol and gemfibrozil, while the Lipitor label lists cyclosporine, gemfibrozil and other CYP3A4 and transporter inhibitors as combinations to avoid or manage. Rosuvastatin, pravastatin, pitavastatin and fluvastatin do not rely on CYP3A4. Poor kidney function points toward a statin whose levels it does not change, such as atorvastatin; ancestry is a reason for care with rosuvastatin, and both the Lipitor and Zocor labels list acute liver failure and decompensated cirrhosis as contraindications.

Side effects drive many switches. The 2018 guideline reports that statin-associated muscle symptoms, usually aches with a normal creatine kinase, are infrequent in trials (1% to 5%) but reported by 5% to 20% of patients in observational studies, and that statins modestly raise the risk of diabetes in people who already have risk factors for it, which it says is not a reason to stop. NICE puts muscle pain on high-intensity statins at about 16% of people, but estimates that only about 1 in 12 of those cases is caused by the statin. Kidney function can be estimated with the eGFR calculator, and raised liver enzymes on a statin are covered in the guide to elevated ALT levels.

Anyone taking a statin should seek medical advice promptly for unexplained muscle pain, tenderness or weakness, especially with fever or feeling unwell, which the Lipitor label lists as warning signs of myopathy, and for yellowing of the skin or eyes, a sign of liver injury. Severe muscle breakdown can damage the kidneys and needs urgent care.

Matching a statin to a real medicine list is the step that takes the most label reading. A pharmacist or resident can ask AskMed which statins avoid CYP3A4 for a patient on a ritonavir-boosted regimen with an eGFR of 25, and get the relevant label sections for each candidate, cited, to check against the local formulary.

Match a statin to a medicine list and kidney function in AskMed:

Frequently asked questions

Is atorvastatin a high-intensity statin?

It can be. In the 2018 AHA/ACC guideline, atorvastatin appears in both the high-intensity group, which lowers LDL cholesterol by 50% or more, and the moderate-intensity group, which lowers it by 30% to 49%, depending on how intensively it is used. Rosuvastatin is the only other statin that reaches high intensity.

Is atorvastatin lipophilic or hydrophilic?

Atorvastatin is lipophilic, like simvastatin, lovastatin, fluvastatin and pitavastatin. Lipophilic statins enter cells by passive diffusion and are mostly cleared by cytochrome P450 enzymes. Rosuvastatin and pravastatin are hydrophilic and more liver-selective.

Which is stronger, atorvastatin or rosuvastatin?

Both reach high intensity. In the LODESTAR trial, rosuvastatin gave a slightly lower mean LDL cholesterol (1.8 against 1.9 mmol/L), but the rate of death, heart attack, stroke or revascularization over three years was similar, and rosuvastatin had more new-onset diabetes and cataract surgery.

Is atorvastatin cleared by the kidneys?

Very little. The FDA label reports that less than 2% is recovered in urine and that kidney disease does not change its plasma levels or its LDL lowering. Atorvastatin is eliminated mainly in bile after metabolism in the liver.

Can someone switch from atorvastatin to another statin?

Yes, under medical supervision. NICE NG238 lists switching to another statin of the same intensity, such as rosuvastatin for someone on atorvastatin, as one option when side effects occur, along with pausing and re-trying the statin or moving to a lower intensity.

Sources

  1. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation. 2019;139(25):e1082-e1143.
  2. National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238). 2023.
  3. US Food and Drug Administration. LIPITOR (atorvastatin calcium) prescribing information. DailyMed.
  4. US Food and Drug Administration. CRESTOR (rosuvastatin calcium) prescribing information. DailyMed.
  5. US Food and Drug Administration. ZOCOR (simvastatin) prescribing information. DailyMed.
  6. US Food and Drug Administration. Pravastatin sodium prescribing information. DailyMed.
  7. US Food and Drug Administration. LIVALO (pitavastatin) prescribing information. DailyMed.
  8. Climent E, Benaiges D, Pedro-Botet J. Hydrophilic or Lipophilic Statins? Front Cardiovasc Med. 2021;8:687585.
  9. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681.
  10. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations (ASCOT-LLA). Lancet. 2003;361(9364):1149-1158.
  11. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Lancet. 2004;364(9435):685-696.
  12. Amarenco P, Bogousslavsky J, Callahan A, et al. High-dose atorvastatin after stroke or transient ischemic attack (SPARCL). N Engl J Med. 2006;355(6):549-559.
  13. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes (PROVE IT-TIMI 22). N Engl J Med. 2004;350(15):1495-1504.
  14. Lee YJ, Hong SJ, Kang WC, et al. Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial. BMJ. 2023;383:e075837.

Cited medical answers
you can trust.

AskMed on iPhone, iPad, Android and the web.